STATICIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Staticin, and when can generic versions of Staticin launch?
Staticin is a drug marketed by Westwood Squibb and is included in one NDA.
The generic ingredient in STATICIN is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Staticin
A generic version of STATICIN was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for STATICIN?
- What are the global sales for STATICIN?
- What is Average Wholesale Price for STATICIN?
Summary for STATICIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 61 |
| DailyMed Link: | STATICIN at DailyMed |
US Patents and Regulatory Information for STATICIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Westwood Squibb | STATICIN | erythromycin | SOLUTION;TOPICAL | 050526-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
